FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and to pharmacy. Disclosed is the use of the dipeptide L-glutamine-L-tryptophanic acid (L-Glu-L-Trp) as an agent for enhancing tissue oxygenation by suppressing (reducing synthesis) of the HIF-1α factor in the diabetic foot. Disclosed is a method of enhancing tissue oxygenation by suppressing (reducing synthesis) of a HIF-1α factor in a diabetic foot consisting in local administration of a dipeptide L-glutamine-L-tryptophanic acid (L-Glu-L-Trp) in dose of 1.0–10.0 mcg/kg of body weight at least once a day for a period required to achieve a therapeutic effect.
EFFECT: technical result consists in the implementation of the declared applications in the treatment of the diabetic foot in diabetic patients.
3 cl, 9 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT SHOWING IMMUNOMODULATING ACTIVITY | 1994 |
|
RU2080120C1 |
| AGENT, ACTIVATING TRANSCRIPTION FACTOR HIF | 2015 |
|
RU2602306C2 |
| METHOD FOR TREATING DIABETIC FOOT SYNDROME BEFORE FORMATION OF ULCEROUS DEFECT USING EXTRACORPORAL SHOCK WAVE THERAPY | 2016 |
|
RU2632683C1 |
| METHOD OF PREPARING SKIN GRAFT FOR FREE AUTODERMOPLASTICS | 2016 |
|
RU2652083C2 |
| WOUND HEALING AGENT POSSESSING IMMUNOSTIMULATORY EFFECT | 2014 |
|
RU2555338C1 |
| TETRAPEPTIDE REGULATING GLUCOSE LEVEL IN DIABETES MELLITUS, PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD FOR ITS APPLYING | 2003 |
|
RU2242241C1 |
| TREATING VASCULAR COMPLICATIONS OF DIABETES | 2010 |
|
RU2545718C2 |
| PEPTIDE FOR MEDICAL TREATMENT OF PANCREATIC DIABETES OF 2ND TYPE AND ITS COMPLICATIONS | 2014 |
|
RU2573933C1 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| AGENT INHIBITING ANGIOGENESIS IN VISUAL ORGAN DISEASE | 2001 |
|
RU2177801C1 |
